Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “

CRVS has been the topic of a number of other reports. Credit Suisse Group lowered shares of Corvus Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $10.00 price target on the stock. in a research report on Monday, May 1st. Cowen and Company reaffirmed a “buy” rating on shares of Corvus Pharmaceuticals in a research report on Tuesday, May 2nd. Finally, Wedbush initiated coverage on shares of Corvus Pharmaceuticals in a research report on Wednesday, August 2nd. They set an “outperform” rating and a $26.00 price target on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Corvus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $19.75.

Shares of Corvus Pharmaceuticals (NASDAQ CRVS) traded down 0.82% during trading on Friday, hitting $14.55. 65,324 shares of the stock traded hands. The firm has a 50 day moving average price of $12.24 and a 200-day moving average price of $12.75. Corvus Pharmaceuticals has a one year low of $8.27 and a one year high of $22.14. The company’s market cap is $304.59 million.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.73) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.76) by $0.03. Analysts anticipate that Corvus Pharmaceuticals will post ($3.18) earnings per share for the current fiscal year.

WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/25/corvus-pharmaceuticals-inc-crvs-lowered-to-hold-at-zacks-investment-research.html.

In other news, major shareholder Holdings A/S Novo acquired 20,000 shares of Corvus Pharmaceuticals stock in a transaction on Friday, June 23rd. The shares were purchased at an average cost of $10.95 per share, for a total transaction of $219,000.00. Following the completion of the purchase, the insider now directly owns 3,244,046 shares of the company’s stock, valued at approximately $35,522,303.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Richard A. Md Miller acquired 25,000 shares of Corvus Pharmaceuticals stock in a transaction on Tuesday, June 13th. The shares were purchased at an average price of $9.88 per share, for a total transaction of $247,000.00. The disclosure for this purchase can be found here.

Large investors have recently made changes to their positions in the company. EcoR1 Capital LLC purchased a new stake in shares of Corvus Pharmaceuticals during the second quarter worth about $9,741,000. Jennison Associates LLC increased its stake in Corvus Pharmaceuticals by 87.4% in the second quarter. Jennison Associates LLC now owns 1,019,013 shares of the company’s stock worth $12,330,000 after buying an additional 475,164 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Corvus Pharmaceuticals during the first quarter worth $8,480,000. JPMorgan Chase & Co. increased its stake in Corvus Pharmaceuticals by 116.0% in the second quarter. JPMorgan Chase & Co. now owns 332,634 shares of the company’s stock worth $4,025,000 after buying an additional 178,658 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Corvus Pharmaceuticals by 37.1% in the second quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock worth $4,520,000 after buying an additional 101,013 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Receive News & Stock Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.